These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


103 related items for PubMed ID: 2581428

  • 1. [Clinical evaluation of Cernilton on benign prostatic hyperplasia].
    Ueda K, Jinno H, Tsujimura S.
    Hinyokika Kiyo; 1985 Jan; 31(1):187-91. PubMed ID: 2581428
    [Abstract] [Full Text] [Related]

  • 2. [Clinical evaluation of cernilton in the treatment of the benign prostatic hypertrophy].
    Horii A, Iwai S, Maekawa M, Tsujita M.
    Hinyokika Kiyo; 1985 Apr; 31(4):739-46. PubMed ID: 2412423
    [Abstract] [Full Text] [Related]

  • 3. [Clinical evaluation of Cernilton in benign prostatic hypertrophy].
    Hayashi J, Mitsui H, Yamakawa G, Suga A, Kai A, Shimabukuro T, Yanagi K, Fujisawa S, Takihara H, Kaneda Y.
    Hinyokika Kiyo; 1986 Jan; 32(1):135-41. PubMed ID: 2421560
    [Abstract] [Full Text] [Related]

  • 4. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost].
    Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K.
    Hinyokika Kiyo; 1990 Apr; 36(4):495-516. PubMed ID: 1696065
    [Abstract] [Full Text] [Related]

  • 5. [A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia].
    Xu J, Qian WQ, Song JD.
    Zhonghua Nan Ke Xue; 2008 Jun; 14(6):533-7. PubMed ID: 18649754
    [Abstract] [Full Text] [Related]

  • 6. [A long-term therapeutic experience with Cernilton in chronic prostatitis].
    Jodai A, Maruta N, Shimomae E, Sakuragi T, Shindo K, Saito Y.
    Hinyokika Kiyo; 1988 Mar; 34(3):561-8. PubMed ID: 3389296
    [Abstract] [Full Text] [Related]

  • 7. [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
    Shaplygin LV, Sivakov AA.
    Urologiia; 2007 Mar; (3):35-7, 39. PubMed ID: 17722618
    [Abstract] [Full Text] [Related]

  • 8. Cernilton for benign prostatic hyperplasia.
    Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G.
    Cochrane Database Syst Rev; 2000 Mar; (2):CD001042. PubMed ID: 10796739
    [Abstract] [Full Text] [Related]

  • 9. WITHDRAWN: Cernilton for benign prostatic hyperplasia.
    Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G.
    Cochrane Database Syst Rev; 2011 May 11; 2011(5):CD001042. PubMed ID: 21563128
    [Abstract] [Full Text] [Related]

  • 10. [Cernilton in the treatment of prostatic adenoma and chronic prostatitis].
    Aslamazov EG, Akhvlediani ND, Vinarov AZ, Aliaev IuG.
    Urologiia; 2007 May 11; (1):52, 54-6. PubMed ID: 17472001
    [Abstract] [Full Text] [Related]

  • 11. [Fushile: a safe and effective therapeutic for benign prostatic hyperplasia].
    Shang XJ, Liu ZY, Liu ZF, Sun YH, Huang YF.
    Zhonghua Nan Ke Xue; 2008 Mar 11; 14(3):227-30. PubMed ID: 18488335
    [Abstract] [Full Text] [Related]

  • 12. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S.
    Int Urol Nephrol; 1996 Mar 11; 28(1):49-53. PubMed ID: 8738619
    [Abstract] [Full Text] [Related]

  • 13. [Conservative treatment of benign prostatic hypertrophy: reevaluation of the effect of eviprostat by subjective symptoms and uroflowmetry].
    Matsuura T, Wakabayashi A, Kaneko S, Kurita T.
    Hinyokika Kiyo; 1986 Jun 11; 32(6):903-6. PubMed ID: 2429533
    [Abstract] [Full Text] [Related]

  • 14. Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews.
    Kim TH, Lim HJ, Kim MS, Lee MS.
    Maturitas; 2012 Nov 11; 73(3):180-5. PubMed ID: 22883375
    [Abstract] [Full Text] [Related]

  • 15. [Clinical study of Eviprostat for the treatment of benign prostatic hyperplasia].
    Song Y, Li NC, Wang XF, Ma LL, Wan B, Hong BF, Na YQ.
    Zhonghua Nan Ke Xue; 2005 Sep 11; 11(9):674-6. PubMed ID: 16209208
    [Abstract] [Full Text] [Related]

  • 16. [Therapeutic effect of Robaveron tablet (KN-7) on urinary disturbance by benign prostatic hypertrophy].
    Sonoda T, Endo H, Maru A, Sasaki K, Kuroda K, Takamura T, Inada F, Rokuzyo M, Ohori T, Kubo T.
    Hinyokika Kiyo; 1985 Mar 11; 31(3):553-62. PubMed ID: 2411118
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y, Zhao XF, Li HZ, Wang W, Zhang Y, Xiao H, Zhang X.
    Chin Med J (Engl); 2007 Mar 05; 120(5):370-4. PubMed ID: 17376305
    [Abstract] [Full Text] [Related]

  • 18. Diagnosis and management of benign prostatic hyperplasia.
    Edwards JL.
    Am Fam Physician; 2008 May 15; 77(10):1403-10. PubMed ID: 18533373
    [Abstract] [Full Text] [Related]

  • 19. [Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia].
    Vontobel HP, Herzog R, Rutishauser G, Kres H.
    Urologe A; 1985 Jan 15; 24(1):49-51. PubMed ID: 2580383
    [Abstract] [Full Text] [Related]

  • 20. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study.
    Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brähler E, Weidner W.
    Eur Urol; 2009 Sep 15; 56(3):544-51. PubMed ID: 19524353
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 6.